(Q36484954)

14 August 2017

1 reference

title

Candida resistance and its clinical relevance (English)

1 reference

14 August 2017

Michael E Klepser

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

26

1 reference

14 August 2017

issue

6 Pt 2

1 reference

14 August 2017

page(s)

68S-75S

1 reference

Mechanisms of fungal resistance: an overview

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Has antifungal susceptibility testing come of age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

High-dose therapy with fluconazole > or = 800 mg day-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

The exciting future of antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Combination treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

Hospital-acquired candidemia. The attributable mortality and excess length of stay

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.68S

10.1592/PHCO.26.6PART2.68S

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference